Search

Your search keyword '"Wong, Kwong-kwok"' showing total 414 results
Start Over Author "Wong, Kwong-kwok"
414 results on '"Wong, Kwong-kwok"'

4. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

Author

Wong, Kwong-Kwok, Bateman, Nicholas W., Ng, Chun Wai, Tsang, Yvonne T. M., Sun, Charlotte S., Celestino, Joseph, Nguyen, Tri V., Malpica, Anais, Hillman, R. Tyler, Zhang, Jianhua, Futreal, P. Andrew, Rojas, Christine, Conrads, Kelly A., Hood, Brian L., Dalgard, Clifton L., Wilkerson, Matthew D., Phippen, Neil T., Conrads, Thomas P., Maxwell, George L., Sood, Anil K., and Gershenson, David M.

Published
2022
Full Text
View/download PDF

9. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.

Author

Treekitkarnmongkol, Warapen, Solis, Luisa M., Sankaran, Deivendran, Gagea, Mihai, Singh, Pankaj K., Mistry, Ragini, Nguyen, Tristian, Kai, Kazuharu, Liu, Jiajun, Sasai, Kaori, Jitsumori, Yoshimi, Liu, Jianwen, Nagao, Norio, Stossi, Fabio, Mancini, Michael A., Wistuba, Ignacio I., Thompson, Alastair M., Lee, Jonathan M., Cadiñanos, Juan, and Wong, Kwong-Kwok

Subjects
AURORA kinases, BREAST cancer, CANCER cell culture, CANCER cell proliferation, TUMOR growth
Abstract

The translation elongation factor eEF1A promotes protein synthesis. Its methylation by METTL13 increases its activity, supporting tumor growth. However, in some cancers, a high abundance of eEF1A isoforms is associated with a good prognosis. Here, we found that eEF1A2 exhibited oncogenic or tumor-suppressor functions depending on its interaction with METTL13 or the phosphatase PTEN, respectively. METTL13 and PTEN competed for interaction with eEF1A2 in the same structural domain. PTEN-bound eEF1A2 promoted the ubiquitination and degradation of the mitosis-promoting Aurora kinase A in the S and G2 phases of the cell cycle. eEF1A2 bridged the interactions between the SKP1-CUL1-FBXW7 (SCF) ubiquitin ligase complex, the kinase GSK3β, and Aurora-A, thereby facilitating the phosphorylation of Aurora-A in a degron site that was recognized by FBXW7. Genetic ablation of Eef1a2 or Pten in mice resulted in a greater abundance of Aurora-A and increased cell cycling in mammary tumors, which was corroborated in breast cancer tissues from patients. Reactivating this pathway using fimepinostat, which relieves inhibitory signaling directed at PTEN and increases FBXW7 expression, combined with inhibiting Aurora-A with alisertib, suppressed breast cancer cell proliferation in culture and tumor growth in vivo. The findings demonstrate a therapeutically exploitable, tumor-suppressive role for eEF1A2 in breast cancer. Editor's summary: Isoforms of the protein synthesis factor eEF1A can either promote or suppress tumor growth. Treekitkarnmongkol et al. found that eEF1A2 teams up with the tumor suppressor PTEN to repress cell cycling. The interaction between eEF1A2 and PTEN resulted in the assembly of a complex of the kinase GSK3β, the mitotic kinase Aurora-A, and the ubiquitin ligase complex SCF in the pre-mitotic phases of the cell cycle. Phosphorylation at a specific site by GSK3β marked Aurora-A for degradation by the SCF complex, reducing progression through mitosis. Accordingly, Aurora-A was more stable and abundant in PTEN-deficient breast cancers, which showed increased proliferation. A two-drug combination that derepressed PTEN and inhibited Aurora-A suppressed tumor growth in mice, suggesting a potential treatment strategy for patients with PTEN-deficient breast tumors. —Leslie K. Ferrarelli [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Low-grade serous ovarian cancer: expert consensus report on the state of the science

Author

Grisham, Rachel N, primary, Slomovitz, Brian M, additional, Andrews, Nicole, additional, Banerjee, Susana, additional, Brown, Jubilee, additional, Carey, Mark S, additional, Chui, Herman, additional, Coleman, Robert L, additional, Fader, Amanda N, additional, Gaillard, Stephanie, additional, Gourley, Charlie, additional, Sood, Anil K, additional, Monk, Bradley J, additional, Moore, Kathleen N, additional, Ray-Coquard, Isabelle, additional, Shih, Ie-Ming, additional, Westin, Shannon N, additional, Wong, Kwong-Kwok, additional, and Gershenson, David M, additional

Published
2023
Full Text
View/download PDF

11. List of contributors

Author

Aftimos, Philippe, primary, Al-Turkmani, M. Rabie, additional, Azim, Hatem A., additional, Bastacky, Sheldon I., additional, Beenhouwer, David O., additional, Behari, Jaideep, additional, Berdasco, María, additional, Biggs, Joseph R., additional, Brandão, Mariana, additional, Campbell, Sheldon, additional, Chan, Wai-Yee, additional, Coleman, William B., additional, Corsi Romanelli, Massimiliano M., additional, Couch, Robin D., additional, Davis, Justin B., additional, Deharvengt, Sophie J., additional, Del Portillo, Armando J., additional, Espina, Virginia, additional, Esteller, Manel, additional, Farver, Carol F., additional, Feldman, Michael D., additional, Fink, Susan L., additional, Flanagan, Margaret, additional, Fredolini, Claudia, additional, Funkhouser, William K., additional, Futschik, Matthias E., additional, Galliera, Emanuela, additional, Gotlieb, Avrum I., additional, Hevner, Robert F., additional, Highsmith, W. Edward, additional, Keene, Christopher Dirk, additional, Key, Nigel S., additional, Koellner, Christine M., additional, Lefferts, Joel A., additional, Lemasters, John J., additional, Lerch, Markus M., additional, Liotta, Lance A., additional, Liu, Youhua, additional, Lu, Karen H., additional, Lukacs, Nicholas W., additional, Ma, Alice D., additional, Martin, Karlyn, additional, Mayerle, Julia, additional, Mensink, Kara A., additional, Mok, Samuel C., additional, Monga, Satdarshan P.S., additional, Montine, Thomas J., additional, Moore, Jason H., additional, Morkel, Markus, additional, Munger, Karl, additional, Nagymanyoki, Zoltan, additional, Nerenz, Robert D., additional, Pang, Alan L.-Y., additional, Petricoin, Emanuel, additional, Ptaschinski, Catherine, additional, Schäfer, Reinhold, additional, Sendler, Matthias, additional, Sepulveda, Antonia R., additional, Sers, Christine, additional, Silverman, Lawrence M., additional, Sonnen, Joshua A., additional, Sotiriou, Christos, additional, Tan, Roderick J., additional, Tsongalis, Gregory J., additional, Wessagowit, Vesarat, additional, Williams, Eli S., additional, Wong, Kwong-Kwok, additional, Zander, Dani S., additional, Zhang, Dong-Er, additional, and Zhou, Weidong, additional

Published
2020
Full Text
View/download PDF

22. Global Analysis of the Deinococcus radiodurans Proteome by Using Accurate Mass Tags

Author

Lipton, Mary S., Paša-Tolić, Ljiljana, Anderson, Gordon A., Anderson, David J., Auberry, Deanna L., Battista, John R., Daly, Michael J., Fredrickson, Jim, Hixson, Kim K., Kostandarithes, Heather, Masselon, Christophe, Markillie, Lye Meng, Moore, Ronald J., Romine, Margaret F., Shen, Yufeng, Stritmatter, Eric, Tolić, Nikola, Udseth, Harold R., Venkateswaran, Amudhan, Wong, Kwong-Kwok, Zhao, Rui, and Smith, Richard D.

Published
2002

23. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance

Author

Leung, Cecilia S., Yeung, Tsz-Lun, Yip, Kay-Pong, Wong, Kwong-Kwok, Ho, Samuel Y., Mangala, Lingegowda S., Sood, Anil K., Lopez-Berestein, Gabriel, Sheng, Jianting, Wong, Stephen T.C., Birrer, Michael J., and Mok, Samuel C.

Subjects
Cell adhesion molecules -- Properties, Drug resistance -- Genetic aspects, Ovarian cancer -- Drug therapy, Fibroblasts -- Genetic aspects, Health care industry
Abstract

The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance In ovarian cancer Is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer. Mechanistically, LPP increased focal adhesion and stress fiber formation to promote endothelial cell motility and permeability. siRNA- mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intratumoral microvessel leakiness. Further studies showed that CAFs regulate endothelial LPP via a calcium-dependent signaling pathway involving microfibrillar-associated protein 5 (MFAP5), focal adhesion kinase (FAK), ERK, and LPP. Thus, our findings suggest that targeting endothelial LPP enhances the efficacy of chemotherapy in ovarian cancer. Our data highlight the importance of CAF-endothelial cell crosstalk signaling in cancer chemoresistance and demonstrate the improved efficacy of using LPP-targeting siRNA in combination with cytotoxic drugs., Introduction High-grade serous ovarian cancer (HGSC) is the most common histological subtype of ovarian cancer and accounts for most ovarian cancer-related deaths. Most HGSCs are diagnosed at a late stage, [...]

Published
2018
Full Text
View/download PDF

26. Supplementary Figure 4 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

34. Data from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legend from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Author

Zaid, Tarrik M., primary, Yeung, Tsz-Lun, primary, Thompson, Melissa S., primary, Leung, Cecilia S., primary, Harding, Tom, primary, Co, Ngai-Na, primary, Schmandt, Rosie S., primary, Kwan, Suet-Ying, primary, Rodriguez-Aguay, Cristian, primary, Lopez-Berestein, Gabriel, primary, Sood, Anil K., primary, Wong, Kwong-Kwok, primary, Birrer, Michael J., primary, and Mok, Samuel C., primary

Published
2023
Full Text
View/download PDF

39. Figure S1 from Expression Analysis of Juvenile Pilocytic Astrocytomas by Oligonucleotide Microarray Reveals Two Potential Subgroups

Author

Wong, Kwong-Kwok, primary, Chang, Yi-Mieng, primary, Tsang, Yvonne T.M., primary, Perlaky, Laszlo, primary, Su, Jack, primary, Adesina, Adekunle, primary, Armstrong, Dawna L., primary, Bhattacharjee, Meenakshi, primary, Dauser, Robert, primary, Blaney, Susan M., primary, Chintagumpala, Murali, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables 1-2 from Genome-Wide Allelic Imbalance Analysis of Pediatric Gliomas by Single Nucleotide Polymorphic Allele Array

Author

Wong, Kwong-Kwok, primary, Tsang, Yvonne T.M., primary, Chang, Yi-Mieng, primary, Su, Jack, primary, Di Francesco, Angela M., primary, Meco, Daniela, primary, Riccardi, Riccardo, primary, Perlaky, Laszlo, primary, Dauser, Robert C., primary, Adesina, Adekunle, primary, Bhattacharjee, Meenakshi, primary, Chintagumpala, Murali, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from Genome-Wide Allelic Imbalance Analysis of Pediatric Gliomas by Single Nucleotide Polymorphic Allele Array

Author

Wong, Kwong-Kwok, primary, Tsang, Yvonne T.M., primary, Chang, Yi-Mieng, primary, Su, Jack, primary, Di Francesco, Angela M., primary, Meco, Daniela, primary, Riccardi, Riccardo, primary, Perlaky, Laszlo, primary, Dauser, Robert C., primary, Adesina, Adekunle, primary, Bhattacharjee, Meenakshi, primary, Chintagumpala, Murali, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

44. Table S2 from Expression Analysis of Juvenile Pilocytic Astrocytomas by Oligonucleotide Microarray Reveals Two Potential Subgroups

Author

Wong, Kwong-Kwok, primary, Chang, Yi-Mieng, primary, Tsang, Yvonne T.M., primary, Perlaky, Laszlo, primary, Su, Jack, primary, Adesina, Adekunle, primary, Armstrong, Dawna L., primary, Bhattacharjee, Meenakshi, primary, Dauser, Robert, primary, Blaney, Susan M., primary, Chintagumpala, Murali, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure S1 & Table S1 from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy

Author

Man, Tsz-Kwong, primary, Chintagumpala, Murali, primary, Visvanathan, Jaya, primary, Shen, Jianhe, primary, Perlaky, Laszlo, primary, Hicks, John, primary, Johnson, Mark, primary, Davino, Nelson, primary, Murray, Jeffrey, primary, Helman, Lee, primary, Meyer, William, primary, Triche, Timothy, primary, Wong, Kwong-Kwok, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Genome-Wide Allelic Imbalance Analysis of Pediatric Gliomas by Single Nucleotide Polymorphic Allele Array

Author

Wong, Kwong-Kwok, primary, Tsang, Yvonne T.M., primary, Chang, Yi-Mieng, primary, Su, Jack, primary, Di Francesco, Angela M., primary, Meco, Daniela, primary, Riccardi, Riccardo, primary, Perlaky, Laszlo, primary, Dauser, Robert C., primary, Adesina, Adekunle, primary, Bhattacharjee, Meenakshi, primary, Chintagumpala, Murali, primary, and Lau, Ching C., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results